J&J Predicts No Stelara Biosimilar Until 2025

After reaching patent settlements with biosimilar drug makers, the company expects to retain exclusivity of its top-selling drug longer than initially expected.

runway
J&J sees a longer LOE horizon for Stelara • Source: Shutterstock

More from Earnings

More from Business